| Date | Title | Description |
| 18.01.2025 | Medicare's Drug Price Negotiations: A New Era for Prescription Costs | In a significant shift, Medicare is stepping into the ring to negotiate drug prices. This change aims to alleviate the financial burden on millions of seniors. The latest announcement includes 15 new drugs, bringing the total to 25. These d... |
| 17.01.2025 | Ozempic, Wegovy and other drugs are among 15 selected for Medicare’s price negotiations | That brings the total to 25 drugs that will have lower price tags for Medicare enrollees.
Together, those 25 drugs account for a third of Medicare spending on prescriptions, Becerra said. Ozempic and Wegovy, in particular, have been scrutin... |
| 04.06.2024 | Analysis Group Researchers Suggest a Novel Approach to Measuring Real-World Treatment Effectiveness for Irritable Bowel Syndrome with Diarrhea | BOSTON, June 4, 2024 /PRNewswire/ -- Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have coauthored a study detailing how treatment-free intervals (TFIs) can be an effective surrogate in r... |
| 15.06.2021 | Salix Will Share TRULANCE® (Plecanatide) Data At The 2021 AANP National Conference | |
| 15.04.2021 | New Report Reveals That More Than One-Third Of IBS Patients Surveyed State It Has Been More Challenging To Manage Their Symptoms During The COVID-19 Pandemic | |
| 30.04.2012 | FDA extends review of SLXP diarrhea drug; Napo explores new indications | There’s no indication that there is a problem with the application and the FDA did not request any additional studies. But it’s the second extension Salix has received in the last week. The FDA last week notified the company of a three-mont... |
| 13.03.2012 | Salix Pharmaceuticals prices $600M loan offering | Under certain circumstances, the notes will be convertible into cash, Salix common stock, or a combination of the two. The initial conversion rate will be 15.1947 shares of Salix’s common stock per $1,000 principal amount of notes. That amo... |
| 07.02.2012 | Priority review for SLXP diarrhea drug, but shouldn’t patients have it by now? | Raleigh, North Carolina-based Salix had a busy 2011 and most of that activity was unrelated to crofelemer. Besides some licensing deals and acquisitions, the company has had its hands full with another gastrointestinal drug. Salix had expec... |
| 20.12.2011 | Salix’s pill version of Relistor succeeds in phase 3; NDA expected in 2012 | Relistor is indicated for treating constipation in patients who have advanced illness and are receiving opioids as part of their palliative care. Opioid medications’ mechanism for fighting pain also affects the gastrointestinal tract, which... |
| 14.12.2011 | Salix files NDA for diarrhea drug despite dispute with partner Napo | Salix licensed crofelemer in 2008 from San Francisco, California drug developer Napo Pharmaceuticals, an agreement that paid Napo $4.5 million and called for Salix to be responsible for development of the compound. Crofelemer had been grant... |
| 17.11.2011 | Salix IBS drug set to start second phase 3 trial in January | Clinical trial enrollment is set to start in January. Salix estimates it will take about two years to complete trials, resubmit a response to the FDA complete response letter and receive an approval decision.
Salix said the proposed design ... |
| 15.11.2011 | Salix IBS drug faces tough questions ahead of new phase 3 clinical trials | Xifaxan is not a new drug. Salix has already received FDA approval on the broad spectrum antibiotic for treating traveler’s diarrhea and hepatic encephalopathy, a brain disorder associated with severe liver disease. The previous approvals c... |
| 08.11.2011 | Salix to acquire Oceana for $300M; adds two products to portfolio | Solesta treats patients who have fecal incontinence. An estimated 15 percent of people in the United States over 50 have the condition. Some patients turn to diarrhea products such as Imodium or fiber. In serious cases, patients may turn to... |
| 30.08.2011 | FDA to review Salix constipation drug Relistor for new indication | Relistor can reduce the constipating effects of opioids without affecting their pain-killing abilities. Salix and drug partner Progenics Pharmaceuticals (NASDAQ:PGNX) want to expand Relistor’s use to treat opioid-induced constipation in pat... |
| 08.08.2011 | Salix IBS drug needs new clinical study; approval at least two years away | During a Monday conference call to discuss second-quarter financial results, Salix CEO Carolyn Logan said that the FDA proposed and the company agreed to form an advisory committee to review the Xifaxan IBS data. That committee will design ... |
| 09.05.2011 | Salix sued by partner for ‘breach’ over HIV-associated diarrhea drug | Salix disclosed the lawsuit Monday morning. The company said in a prepared statement that the lawsuit is baseless and Napo’s claims are without merit. Salix added that it plans to continue with the development and commercialization of the d... |
| 05.05.2011 | New IBS drug: Salix will make case for approval at June meeting with FDA | Executives for Morrisville, North Carolina-based Salix described the plan to analysts during a conference call to discuss first-quarter earnings. Salix has been studying Xifaxan as a new IBS treatment and had expected FDA approval in March.... |
| 20.04.2011 | Three patents awarded for drug from N.C. pharma Salix | Salix said Wednesday that a patent has been granted for methods of treating traveler’s diarrhea with rifaximin. That patent expires July 24, 2029. Two other patents were issued relating to the pharmaceutical composition of rifaximin in mult... |
| 06.04.2011 | Salix expands drug delivery technology partnership with Indian pharma | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recov... |
| 29.03.2011 | North Carolina pharma R&D funding: A snapshot of 2010 | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 08.03.2011 | Salix gets FDA letter on IBS drug, but company won’t disclose details | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 24.02.2011 | Drug approval now unlikely for Salix bowel treatment | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 07.02.2011 | Salix Pharmaceuticals pays $60m up front for constipation drug Relistor | Salix, which specializes in gastrointestinal treatments, could pay Progenics another $90 million if the company reaches certain regulatory milestones in the United States. Salix will fund development, registration and commercialization cost... |
| 05.02.2009 | Napo Pharm raises seed money for its anti-diarrheal drug | Napo Pharmaceuticals, a South San Francisco-based drug company, just closed a round of initial funding from Asset Management. The undisclosed sum is earmarked for its subsidiary Crofelemer Access Program Global, which makes an anti-diarrhea... |
| - | Salix files NDA for diarrhea drug despite dispute with partner Napo | Gastrointestinal therapeutics firm Salix Pharmaceuticals (NASDAQ:SLXP) is pressing ahead with a drug candidate to treat diarrhea in AIDS patients despite a deteriorating relationship with its drug partner that has led to a contract dispute ... |
| - | Salix Pharmaceuticals pays $60m up front for constipation drug Relistor | Salix Pharmaceuticals has brought another gastrointestinal product into its portfolio with a licensing agreement for Progenics Pharmaceutical’s constipation drug Relistor.
Morrisville, North Carolina-based Salix (NASDAQ:SLXP) is paying New ... |
| - | Salix gets FDA letter on IBS drug, but company won’t disclose details | Salix Pharmaceuticals finally received formal U.S. Food and Drug Administration notice that the agency would not approve the company’s irritable bowel syndrome drug, but so far, the company is saying little else.
Morrisville, North Carolina... |
| - | Salix IBS drug set to start second phase 3 trial in January | The Salix Pharmaceuticals (NASDAQ:SLXP) irritable bowel syndrome drug candidate that failed to win U.S. Food and Drug Administration approval earlier this year is on its way to starting another phase 3 clinical trial.
The Raleigh, North Car... |
| - | FDA extends review of SLXP diarrhea drug; Napo explores new indications | AIDS patients expecting approval of a new HIV-associated diarrhea treatment in June must wait at least another three months for a decision.
Salix Pharmaceuticals (NASDAQ:SLXP) had been scheduled for a June 5 decision date on its experimenta... |
| - | Salix’s pill version of Relistor succeeds in phase 3; NDA expected in 2012 | Salix Pharmaceuticals (NASDAQ:SLXP) is a step closer to bringing to the U.S. Food and Drug Administration a once-a-day pill version of injectable constipation drug Relistor.
The Raleigh pharmaceutical company released successful phase 3 cli... |
| - | North Carolina pharma R&D funding: A snapshot of 2010 | Research and development spending dollars reached a record $67.4 billion in 2010, a $1.5 billion increase compared with 2009.
North Carolina’s life science companies are certainly part of that mix. A look at the annual reports from public c... |
| - | Salix Pharmaceuticals prices $600M loan offering | Gastrointestinal treatments firm Salix Pharmaceuticals (NASDAQ:SLXP) aims to raise $600 million in debt financing.
The Raleigh, North Carolina company has priced the $600 million offering of convertible senior notes, which is open to qualif... |
| - | Salix sued by partner for ‘breach’ over HIV-associated diarrhea drug | Three years ago, Salix Pharmaceuticals (NASDAQ:SLXP) licensed a promising compound with the goal of developing a new treatment for chronic diarrhea in HIV patients.
Morrisville, North Carolina-based Salix paid Napo Pharmaceuticals $5 millio... |
| - | Salix IBS drug faces tough questions ahead of new phase 3 clinical trials | When Salix Pharmaceuticals (NASDAQ:SLXP) disclosed that the U.S. Food and Drug Administration would not approve its drug Xifaxan for the new indication of irritable bowel syndrome, the gastrointestinal treatments company made clear it belie... |
| - | Drug approval now unlikely for Salix bowel treatment | An irritable bowel syndrome treatment that Salix Pharmaceuticals expected would be approved by early March now looks like it won’t get the OK from the U.S. Food and Drug Administration.
Morrisville, North Carolina-based Salix (NASDAQ:SLXP) ... |
| - | FDA to review Salix constipation drug Relistor for new indication | The U.S. Food and Drug Administration will review a constipation drug marketed by Salix Pharmaceuticals (NASDAQ:SLXP) to consider adding a new indication for the product.
Relistor is an injectable drug approved in 2008 to treat constipation... |
| - | Salix to acquire Oceana for $300M; adds two products to portfolio | Gastrointestinal treatments company Salix Pharmaceuticals (NASDAQ:SLXP) will acquire Oceana Therapeutics for $300 million cash in a deal that brings two more products to its portfolio — both of them medical devices.
Morrisville, North Carol... |
| - | Salix expands drug delivery technology partnership with Indian pharma | Salix Pharmaceuticals is extending an agreement with an Indian pharmaceutical partner to give Salix exclusive global rights, except for India, to a key drug-delivery technology.
Morrisville, North Carolina-based Salix (NASDAQ:SLXP) in 2009 ... |
| - | Three patents awarded for drug from N.C. pharma Salix | Salix Pharmaceuticals (NASDAQ:SLXP) is still working through issues that kept regulators from approving a drug for irritable bowel syndrome, but the North Carolina company is securing additional patent rights on the compound for other indic... |
| - | New IBS drug: Salix will make case for approval at June meeting with FDA | Salix Pharmaceuticals (NASDAQ:SLXP) believes that there’s enough solid data available now to warrant U.S. Food and Drug Administration approval of its new irritable bowel syndrome drug and at a meeting with the agency next month, the compan... |
| - | Priority review for SLXP diarrhea drug, but shouldn’t patients have it by now? | AIDS patients who frequently suffer from diarrhea may now finally see some light at the end of the tunnel for a new drug developed to help them.
The U.S. Food and Drug Administration has granted priority review for Salix Pharmaceuticals‘ (N... |
| - | Salix IBS drug needs new clinical study; approval at least two years away | Salix Pharmaceuticals (NASDAQ:SLXP) needs another clinical study on its irritable bowel syndrome treatment, which means it could take two more years for the drug to secure regulatory approval.
That’s two more years than the gastrointestinal... |
